Healthcare / Drug Manufacturers - Specialty & GenericNasdaqGM
$4.30
-0.14 (-3.04%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $48.7M · quality 80.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$309M
P/E
15.4x
↓EV/EBITDA
6.4x
↓ROE
11.7%
↑Gross Margin
68.6%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
45.6%
FCF / Net income
1.85x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $94.6M · net income $23.3M · FCF $43.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $94.6M | $94.6M | $138.7M | $139.9M | $110.8M | $133.7M | $125.0M | $26.7M | $477.1M | $12.3M | $15.0M | — | — | — | — | — | — | — |
| Net Income | $23.3M | $23.3M | $59.2M | $68.1M | $33.9M | $69.5M | $56.3M | $-7.2M | $421.8M | $-36.2M | $-39.7M | $-39.5M | $-265.5M | $-17.2M | $-14.1M | $29.1M | $-50.3M | $-19.4M |
| EBITDA | $24.3M | $24.3M | $70.5M | $84.2M | $43.2M | $89.6M | $85.0M | $-1.8M | $355.2M | $-18.7M | $-30.8M | $-30.7M | $-209.3M | $-23.1M | $-22.1M | $-30.8M | $-12.1M | $-11.4M |
| EPS | 0.32 | 0.32 | 0.82 | 0.95 | 0.46 | 0.91 | 0.71 | -0.15 | 5.18 | -0.46 | -0.69 | -0.73 | -4.97 | -0.33 | -0.27 | 0.09 | -1.12 | -0.52 |
| Gross Margin | 68.6% | 68.6% | 77.4% | 87.3% | 90.6% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | 25.1% | 25.1% | 50.4% | 59.8% | 38.5% | 66.7% | 67.6% | -8.7% | 74.4% | -153.6% | -206.9% | — | — | — | — | — | — | — |
| Net Margin | 24.6% | 24.6% | 42.7% | 48.6% | 30.6% | 52.0% | 45.1% | -27.1% | 88.4% | -295.3% | -264.9% | — | — | — | — | — | — | — |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | 0.00 | 0.12 | 0.14 | 0.00 | — | — |
| Current Ratio | 3.25 | 3.25 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $43.1M | $43.1M | $48.7M | $94.8M | $41.6M | — | — | $-18.2M | $68.8M | $-18.5M | $-116.8M | $11.0M | $14.1M | $57.6M | $-20.8M | $25.3M | $-11.4M | $-8.8M |
| Returns | ||||||||||||||||||
| ROE | 11.7% | 11.7% | 27.4% | 34.6% | 19.9% | 39.8% | 43.4% | -7.4% | 409.9% | 11.2% | 13.8% | 13.9% | 107.7% | -101.2% | -49.8% | 71.4% | 389.9% | 150.2% |
| Valuation | ||||||||||||||||||
| P/E | 15.37 | 15.37 | 7.72 | 6.06 | 15.74 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 6.39 | 6.39 | 4.26 | 3.13 | 10.05 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 1.56 | 1.56 | 2.11 | 2.10 | 3.13 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | -31.8% | -31.8% | -0.9% | 26.3% | — | 7.0% | 367.3% | -94.4% | 3788.3% | -18.1% | — | — | — | — | — | — | — | — |
| EPS Growth | -61.0% | -61.0% | -13.7% | 106.5% | — | 28.2% | 573.3% | -102.9% | 1226.1% | 33.3% | 5.5% | 85.3% | -1406.1% | -22.2% | -400.0% | 108.0% | -115.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
6.1%
EPS terminal req.
$0.38
Spread vs growth
-67.1%
5Y implied EPS CAGR
7.6%
EPS terminal req.
$0.46
Spread vs growth
-68.6%
10Y implied EPS CAGR
8.8%
EPS terminal req.
$0.74
Spread vs growth
-69.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-29.2%
Start / end P/E
7.4x → 13.5x
EPS bridge
0.82 → 0.32
Residual
-49.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.